BD (NYSE:BD) announced today that it acquired cloud-based pharmacy management application developer MedKeeper.
Franklin Lakes, N.J.-based BD said in a news release that MedKeeper strategically complements its existing presence in the pharmacy, with solutions for compounding, logistics workflow, controlled substance management and inventory optimization.
MedKeeper’s platform will be made part of BD’s existing portfolio of connected medication management capabilities to optimize the preparation of compounded medications and improve the IV workflow.
“Preparing the right dose for patients requires a combination of factors – including personnel, training, and compliance. Pharmacy leaders require IV workflow management technology that is personalized to their needs and works within their environment,” Mike Garrison, worldwide president of medication management solutions at BD, said in the release. “Adding MedKeeper to our portfolio will enable us to offer our customers easy-to-use, customizable solutions that make meaningful and incremental progress in IV workflow management.”
BD said in the release that the combination of manual and technical tools for IV workflow management is too common among pharmacies at present, so the addition of MedKeeper to BD’s medication management solutions portfolio will create a new way to meet needs with cloud-based technology.
The two companies said they will provide customers with “flexibility and capabilities in meeting industry standards for preparing compounded medications, incorporating the latest regulatory guidance.” They aim to ensure that workflows best support each customer’s environment and creates an efficient environment for frontline clinicians.
“Demands in today’s pharmacy environment, such as COVID-impacted labor shortages and changing regulatory requirements, have further exacerbated the need for customizable pharmacy software solutions to support flexible, directed workflow, inventory tracking and reporting needs in sterile and non-sterile compounding,” Garrison added. “Manual, time-consuming procedures that might once have been ‘good enough’ now can be replaced and augmented by software that enables pharmacists to provide a higher standard of care.”
The transaction is expected to be immaterial to BD’s fiscal 2022 financial results.